(Total Views: 354)
Posted On: 09/10/2020 9:09:23 PM
Post# of 36567
Another excerpt from the Seeking Alpha Article - seems like we will get China deal on swine flu soon?
This valuation conservatively estimates the potential market penetration in China and also assumes that COVID-19 does not mutate and require new vaccinations year after year, like the annual flu shot. It is also likely that the Ii-Key will be used against the arising swine flu in China, although that is also not taken into account in this model.
Generex shares, calculated to be worth $5.44 based on the current anticipated licensing agreements overseas only and ignoring all other aspects of Generex's business, appear undervalued. This is based on the potential of the Ii-Key vaccine to produce royalties in Malaysia and China. However, these royalties are completely speculative and revenues could vary considerably from these forecasts, higher and lower.
https://seekingalpha.com/article/4373034-gene...ompetition
This valuation conservatively estimates the potential market penetration in China and also assumes that COVID-19 does not mutate and require new vaccinations year after year, like the annual flu shot. It is also likely that the Ii-Key will be used against the arising swine flu in China, although that is also not taken into account in this model.
Generex shares, calculated to be worth $5.44 based on the current anticipated licensing agreements overseas only and ignoring all other aspects of Generex's business, appear undervalued. This is based on the potential of the Ii-Key vaccine to produce royalties in Malaysia and China. However, these royalties are completely speculative and revenues could vary considerably from these forecasts, higher and lower.
https://seekingalpha.com/article/4373034-gene...ompetition
(0)
(0)
